VSTM icon

Verastem

6.16 USD
-0.07
1.12%
Updated Jul 31, 11:04 AM EDT
1 day
-1.12%
5 days
16.23%
1 month
48.43%
3 months
-17.76%
6 months
1.32%
Year to date
-5.08%
1 year
136.92%
5 years
-61.69%
10 years
-92.97%
 

About: Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.

Employees: 78

0
Funds holding %
of 7,323 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

93% more call options, than puts

Call options by funds: $605K | Put options by funds: $314K

83% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 12

50% more funds holding in top 10

Funds holding in top 10: 2 [Q4 2024] → 3 (+1) [Q1 2025]

48% more capital invested

Capital invested by funds: $176M [Q4 2024] → $261M (+$85.1M) [Q1 2025]

40% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 25

9% more funds holding

Funds holding: 91 [Q4 2024] → 99 (+8) [Q1 2025]

6.22% more ownership

Funds ownership: 77.83% [Q4 2024] → 84.05% (+6.22%) [Q1 2025]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$12
95%
upside
Avg. target
$13
111%
upside
High target
$14
127%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
RBC Capital
Leonid Timashev
95%upside
$12
Outperform
Maintained
25 Jun 2025
HC Wainwright & Co.
Sean Lee
127%upside
$14
Buy
Maintained
9 May 2025

Financial journalist opinion

Based on 5 articles about VSTM published over the past 30 days

Neutral
Business Wire
2 days ago
Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its second quarter 2025 financial results and business updates on Thursday, August 7, 2025, at 4:30 pm ET. To access the conference call, please dial (800) 715-9871 (U.S.) or (646) 307-1963 (international) and enter the passcode 1210516 at.
Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025
Neutral
Business Wire
1 week ago
Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, for the first-line treatment of patients with KRAS G12D-mutated locally advanced or metastatic adenocarcinoma of the pancreas (PDAC) and for the treatment of patients with K.
Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer
Positive
Seeking Alpha
2 weeks ago
Verastem: The Market Is Ignoring The Progress
FDA approval of AVMAPKI FAKZYNJA CO-PACK marks a transformative milestone, positioning Verastem as a commercial-stage leader in KRAS-mutant LGSOC treatment. Verastem's strong cash position and promising pipeline, including VS-7375 for KRAS G12D, offer significant upside with multiple near-term catalysts ahead. Risks include slow commercial uptake, pipeline uncertainty, and potential future dilution, but current valuation under $5 presents an attractive entry point.
Verastem: The Market Is Ignoring The Progress
Neutral
Business Wire
2 weeks ago
Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the primary analysis of the Phase 2 RAMP 201 clinical trial was published online in the Journal of Clinical Oncology (JCO). The data reported in the publication showed that avutometinib plus defactinib demonstrated a confirmed overall response rate (ORR) of 31% in all patients with recurrent low-grade.
Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology
Neutral
Business Wire
3 weeks ago
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of stock options to purchase 45,000 shares of its common stock to four new employees. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee's acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c).
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neutral
Business Wire
1 month ago
Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that updated results from the Phase 1/2 FRAME study conducted by The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust were published online in Nature Medicine. The full manuscript, titled “Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial,” w.
Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer
Positive
Seeking Alpha
1 month ago
Verastem: Approval Secured, Moving On To PDAC And KRAS G12D-Related Cancers
Recent pipeline updates highlight promising new product candidates advancing to late-stage trials, strengthening my confidence in future growth. The company maintains a solid financial position, with strong cash reserves and prudent expense management supporting ongoing R&D initiatives. Key strengths include a diversified portfolio and robust clinical data, though regulatory risks and competition remain notable challenges.
Verastem: Approval Secured, Moving On To PDAC And KRAS G12D-Related Cancers
Neutral
Business Wire
1 month ago
Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the first patient has been dosed in VS-7375-101, the U.S. Phase 1/2a clinical trial evaluating VS-7375, a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor, in patients with advanced KRAS G12D mutant solid tumors. “We continue to make strong progress against our strategic priorities and key mil.
Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors
Neutral
Business Wire
1 month ago
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced positive updated data from the dose escalation phase of the Phase 1/2 trial of GFH375 (known as VS-7375 in the U.S.). As of May 16, 2025, 23 efficacy-evaluable patients with pancreatic ductal adenocarcinoma (PDAC) and 12 efficacy-evaluable patients with non-small cell lung cancer (NSCLC) achieved an overall.
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor
Positive
Zacks Investment Research
2 months ago
VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval
Verastem Oncology jumps 22% on FDA nod for Avmapki Fakzynja, the first approved KRAS-mutant LGSOC therapy, with strong early data in a pancreatic cancer study.
VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval
Charts implemented using Lightweight Charts™